Vitiliginous vs pigmented skin response to intradermal administration of interferon gamma. 1993

A Gilhar, and E Aizen, and N Ohana, and A Etzioni
Skin Research Laboratory, Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa.

METHODS Decreased sensitization and elicitation of contact allergens in vitiliginous skin has been described. This may be related to altered epidermal Langerhans cell migration with bound hapten to dermis and draining lymph nodes. The aim of the present study was to detect the potential ability of vitiliginous skin to respond to an in vivo immunologic stimulus such as intradermal injections of interferon gamma (IFN-gamma). Vitiliginous and normal pigmented skin of each patient was injected intradermally with 10 micrograms of recombinant IFN-gamma diluted in 0.1 mL of sterile water for 3 consecutive days. On day 5, punch biopsy specimens were obtained from the injected sites. Histologic and immunohistochemical staining was performed on all sections. The cryostat sections were stained with adenosine triphosphatase as well as with the indirect immunoperoxidase technique employing murine monoclonal antibodies to HLA-DR, ICAM-1, CD1, CD11a, and CD18. RESULTS HLA-DR and ICAM-1 expression by epidermal cells, combined with perivascular accumulation of mononuclear cells with CD11a and CD18 expression, was observed in all sites injected with IFN-gamma. However, absence of an effect on the epidermal Langerhans cell population was noted only on the vitiliginous skin. CONCLUSIONS The reactivity of depigmented and pigmented skin was found to be different after IFN-gamma administration, with fewer CD1-positive cells in the depigmented skin. As adenosine triphosphatase staining also showed fewer positive cells, it may be concluded that no effect on the migration of epidermal Langerhans cells was noted in the involved skin. This may shed light on the immunologic aberration seen in vitiliginous skin.

UI MeSH Term Description Entries
D007271 Injections, Intradermal The forcing into the skin of liquid medication, nutrient, or other fluid through a hollow needle, piercing the top skin layer. Intradermal Injections,Injection, Intradermal,Intradermal Injection
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006684 HLA-DR Antigens A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS. HLA-DR,Antigens, HLA-DR,HLA DR Antigens
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000251 Adenosine Triphosphatases A group of enzymes which catalyze the hydrolysis of ATP. The hydrolysis reaction is usually coupled with another function such as transporting Ca(2+) across a membrane. These enzymes may be dependent on Ca(2+), Mg(2+), anions, H+, or DNA. ATPases,Adenosinetriphosphatase,ATPase,ATPase, DNA-Dependent,Adenosine Triphosphatase,DNA-Dependent ATPase,DNA-Dependent Adenosinetriphosphatases,ATPase, DNA Dependent,Adenosinetriphosphatases, DNA-Dependent,DNA Dependent ATPase,DNA Dependent Adenosinetriphosphatases,Triphosphatase, Adenosine
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014820 Vitiligo A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached.

Related Publications

A Gilhar, and E Aizen, and N Ohana, and A Etzioni
January 1989, Archives of dermatological research,
A Gilhar, and E Aizen, and N Ohana, and A Etzioni
February 1984, Archives of dermatology,
A Gilhar, and E Aizen, and N Ohana, and A Etzioni
March 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research,
A Gilhar, and E Aizen, and N Ohana, and A Etzioni
October 1983, International journal of dermatology,
A Gilhar, and E Aizen, and N Ohana, and A Etzioni
June 1989, Lancet (London, England),
A Gilhar, and E Aizen, and N Ohana, and A Etzioni
September 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
A Gilhar, and E Aizen, and N Ohana, and A Etzioni
December 1987, Leprosy review,
A Gilhar, and E Aizen, and N Ohana, and A Etzioni
February 1963, Annals of the New York Academy of Sciences,
A Gilhar, and E Aizen, and N Ohana, and A Etzioni
March 1987, Contact dermatitis,
Copied contents to your clipboard!